Table 1.

Dose and duration of denosumab for treating spinal GCT

First author	Location	Dose	Duration (months)	Results	Side effects
Duan P-G et al9	T11 and T12 vertebra	Not reported	12	No progression with calcification and regression of tumour	Not reported
Law GW et al17	C3 vertebra	120 mg monthly for 9 months and every 2 months for 1 year	21	No progression during treatment, Disease progression at 6 months after stop denosumab	Not reported
Goldschlager T et al4	C, T and L vertebra	120 mg monthly with initial loading dose on days 8 and 15	6	No progression with calcification and regression of tumour	None
Nakazawa T et al18	C5 vertebra	120 mg monthly	24	Surrounding sclerosis and regression of tumour	None
Mattei TA et al19	C2 vertebra	120 mg weekly for 3 weeks then 120 mg monthly	16	Newly formed cortical bone with regression of tumour	None
Bukata SV et al20	C, T, and L vertebra	120 mg monthly with initial loading dose on days 8 and 15	34–74	Complete response 12.6%, partial response 35.9%, stable 50.5%, and progression 1%	ONJ, AFF, hypercalcemia

AFF, atypical femoral fracture; C, cervical; GCT, giant cell tumour; L, lumbar; ONJ, osteonecrosis of the jaw; T, thoracic.